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ABSTRACT                                                            
The present study is aimed at the overall improvement in the efficacy, reduction in toxicity and enhancement 
of therapeutic index of 5-fluorouracil. Biodegradable microparticulate delivery system of 5-fluorouracil has 
been developed by solvent evaporation technique by using polymethacrylate polymers like eudragit L100, 
eudragit S100, eudragit P4135F and methylcellulose. Four different formulations were prepared by using 
these polymers in drug to polymer ratio of 1:2. The formulations were evaluated with respect to particle size 
analysis, entrapment efficiency, in vitro drug release studies, in vivo drug targeting studies and stability 
studies. The formulated magnetic microspheres were found to be spherical with average particle size of 3-12 
µm in diameter and incorporation efficiency up to 78.80%. In vitro drug release after 12 hr was 86.41 %, 
92.84 %, 79.88 % and 82.38 % for formulation F1, F2, F3 and F4 respectively. Formulation F2 with highest 
drug content was selected for in-vivo drug targeting studies. The average targeting efficiency of drug loaded 
microspheres was found to be 26.16 % of the injected dose in liver, 11.40 % in lungs, and 15.08 % in spleen, 
whereas the concentration of pure drug was 15.52 % in liver, 9.0 % in lungs, and 9.50 % in spleen. These 
results reveal that the drug loaded microspheres showed preferential drug targeting to liver followed by 
spleen and lungs. Stability studies revealed that 4º C is the most suitable temperature for storage of 5 - 
fluorouracil loaded microspheres. Overall, this study showed that the 5 - fluorouracil can be formulated in a 
microparticulate drug delivery system by using various polymers and it showed significant prolonged drug 
release.  
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INTRODUCTION 
The necessity and advantages of colon-specific drug delivery systems have been well recognized and 
documented. In addition to providing more effective therapy of colon related diseases such as irritable bowel 
syndrome, inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis, colon specific 
delivery has the potential to address important unmet therapeutic needs including oral delivery of 
macromolecular drugs. It has been reported that at least 1 million Americans are believed to have IBD with 
15000 - 30000 new cases diagnosed annually
1. Studies indicated that absorption enhancers performed more 
effectively in the colon than in the upper gastrointestinal (GI) tract 
2. Drug delivery devices that specifically 
deliver active agents to the colon have been recognized as having important therapeutic advantages. A large 
number of colonic conditions could effectively be treated more efficaciously if the active ingredient is 
released locally. Examples of such colonic disorders include Crohn's disease, ulcerative colitis, colorectal 
cancer and constipation
3. Most of the conventional drug delivery systems for treating the colon disorders 
such as bowel disease (e.g. irritable bowel syndrome, ulcerative colitis, crohn’s disease  etc), infectious 
diseases (amoebiasis) and colon cancers are failing as the drugs do not reach the site of action in appropriate 
concentrations.  Thus,  an effective and safe therapy of these colonic disorders, using site specific drug 
delivery system is a challenging task to the pharmaceutical technologists
4. Colon cancer is the second most 
cause of death after lung cancer by cancer diseases. Many different drugs or drug combinations have been 
tested for a successful therapy. At present, the standard regimen is an intravenous bolus injection of 5-
fluorouracil (5-FU) modulated by leucovorin (LV)
5-6. Only few approaches for an oral administration of 
anticancer drugs in the treatment of colon cancer have been described in literature. Recently, enzyme-
dependent tablet-based systems have been proposed, which might allow an efficient treatment combined with 
a reduction of adverse effects
7. Alternatively, pH-dependent drug release systems have been developed for 
the 5-FU release in the colon 
8.  For at least forty years, 5-fluorouracil (5-FU) has been the mainstay of 
treatment for patients with metastatic colorectal cancer. Biochemical modulation of 5-FU has been 
investigated in an attempt to identify the most efficacious form of administration. Folinic acid (FA) is shown 
to increase the rate of objective response when given in combination with 5-FU and prolongs progression 
free survival with a slightly improved overall survival 
9. 5-Fluorouracil (5-FU) is an antimetabolite of the 
pyrimidine analog class which is widely used alone or in combination chemotherapy regimens. After 
intravenous injection of 5-FU, it is rapidly distributed and eliminated with an apparent terminal half-life of 8-
20 m 
10. 5-FU is poorly absorbed after oral administration with extremely variable bioavailability 
10. These 
disadvantages make it an appropriate candidate for microencapsulation. Indeed, microencapsulation using 
biodegradable and non biodegradable polymers has already been employed to achieve sustained release of 
anticancer drugs such as 5-FU
11-12
Accurately weighed polymers were dissolved in 10 ml of acetone and 5 ml of ethanol in drug: polymer ratio 
of 1: 2 to form a homogenous polymer solution. Core material i.e. 5-Fluorouracil was added to the polymer 
solution and mixed thoroughly. The organic phase was slowly poured at 15
. Furthermore, there is no controlled-release dosage form of 5-FU for oral 
delivery, although this would be particularly useful in cancer therapy. Hence in this study, an attempt is being 
made to prepare microparticulate drug delivery system of  5  –  fluorouracil using solvent evaporation 
technique employed for drug targeting and as drug carriers.  
 
MATERIALS AND METHODS 
 5-Fluorouracil was a kind gift sample from Intas Pharmaceuticals Ltd. Ahmedabad. Eudragit L100, Eudragit 
S100 and Eudragit P4135F were received from Degussa India Pvt. Ltd, Mumbai. Ethyl cellulose, Liquid 
paraffin (light),     n- hexane and petroleum ether were generously gifted by Hi media Laboratories Pvt Ltd. 
Mumbai. 
Formulation of Microspheres 
Emulsification - solvent evaporation method 
0C in to liquid paraffin (100 ml) 
containing 1 % w/w of span 20 with stirring at 800 rpm to form a smooth emulsion. Thereafter, it was Mudgal S et al / IJRAP 2010, 1 (1) 160-168 
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allowed to attain room temperature and stirring was continued until residual acetone evaporated and smooth 
walled, rigid and discrete microspheres were collected by decantation and the product was washed with 
petroleum ether (40-60
0C ) or n- hexane or any other organic solvents, washing was repeated for four times 
and dried at room temperature for 3 h. The microspheres were then stored in a desiccator over fused calcium 
chloride. Three batches were prepared with different proportion of core to coat materials (drug: polymer)
 13-
15. 
 
Evaluation of Magnetic Microspheres 
Particle size analysis  
Scanning electron microscopy has been used to determine particle size distribution, surface topography, 
texture and to examine the morphology of fractured or  sectioned surface. SEM is probably the most 
commonly used method for characterizing drug delivery systems, owing in large part to simplicity of sample 
preparation. Scanning electron was carried out by using JEOL JSMT-330A scanning microscope (Japan). 
Dry microspheres were placed on an electron microscope brass stub and coated with gold in an ion sputter. 
Picture of microspheres was taken by random scanning of the stub
14,16. 
 
Estimation of drug encapsulation efficiency 
To determine the entrapment efficiency, 50 mg of drug loaded microspheres were washed with 10 ml of 
phosphate buffer to remove the surface- associated drug. The absorbance of the filtrate was taken at 266 nm 
to estimate the surface drug content. The filtered microspheres were then digested in a small amount of 
phosphate buffer to release the entrapped drug from the microspheres. The drug was then extracted into the 
buffer by making up the volume to 100ml with the phosphate buffer and keeping it overnight in a metabolic 
shaker with slight shaking. The solution was then filtered and the drug content analyzed 
spectrophotometrically at 266 nm
17. The results are shown in Table no. 1. 
 
                                                                     Practical drug content 
 Percentage entrapment efficiency =      ----------------------------------     X   100                                           
Entrapped drug content  
 
In vitro drug release studies  
 The drug dissolution tests of microspheres were carried out by the paddle method specified in the US 
Pharmacopoeia XXI.  Microspheres were weighed (weight equivalent to 50 mg of drug) were filled in tea 
bags .The tea bag tied using thread with paddle and  900 ml of  different  buffers (pH 1.2 & 7.4)  as 
dissolution medium. Rotated at 100 rpm and thermostatically controlled at 37
o.  Perfect sink conditions 
prevailed during the dissolution tests.  The sample was withdrawn at a suitable interval from the dissolution 
vessel and assayed at 266 nm by using UV-Visible spectrophotometer (UV-1201 Shimadzu, Japan) at 266 
nm
13, 18, 14, 19. 
 
In vivo drug targeting studies  
This study was carried out after obtaining the due permission for conduction of experiments from relevant 
ethics committee (K.L.E.S’s College of Pharmacy, Belgaum) which is registered for “Teaching and Research 
on Animals” by committee for the purpose of control and supervision of experiments on animal, Chennai 
(Registration number 221/CPCSEA).
 
This study was carried out to compare the targeting efficiency of cisplatin  loaded  magnetic 
microspheres  with that of free drug in terms of percentage increase in targeting to various organs of 
reticuloendothelial system like liver, lungs, spleen and kidneys. Experiments were performed on rats of 225-
235  g  weight. All the experiments were carried out in accordance with the protocols approved by the 
Institutional animal ethics committee (K.L.E.S College, Belgaum, India).  Mudgal S et al / IJRAP 2010, 1 (1) 160-168 
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Ten healthy male Albino Wistar rats of weighing 200-250 gm were selected, a constant day and night cycle 
was maintained and they were fasted for 12 hr. The animals were divided into 2 groups. Each containing five 
mice group I received microspheres equivalent to 2.5 mg of 5-fluorouracil in the caudal vein after 
redispersing them in sterile phosphate buffer saline solution. Microspheres from batch F2 were selected for 
the study. Group-II received 2.5 mg of pure 5-fluorouracil intravenously.  
After 6 h the mice were sacrificed and their liver, lungs, and spleen were excised, rinsed, blotted, dry 
and weighted. The individual organs of each mouse were homogenized in 8.0 ml PBS (pH 7.4) and 
centrifuged to obtain supernatant 
20-21.  
Extraction procedure 
The plasma or supernatant of tissue homogenate was mixed with 0.1 ml of 0.25 M NaH2PO4  buffer and 
extracted with 6.0 ml of ethyl acetate. After centrifugation at 5000 rpm for 5 min, 3 ml organic layer was 
evaporated at 55° C. The residue was redissolved in triple distilled water and analyzed with UV detector at 
280 nm. 
 
Stability studies  
Information on the stability of drug substance is an integral part of systematic approach to stability 
evaluation. The purpose of stability testing is to provide evidence on how the quality of a drug substance or 
drug product varies with time under influence of the variety of environmental factors such as temperature, 
humidity and light, and to establish a shelf life for the drug product and recommended storage conditions. All 
4 batches of microspheres were tested for stability. All the preparations were divided into 3 sets and were 
stored at, 4ºC in refrigerator, 30º C ± 2ºC  / 65 %  ± 5 % RH in humidity control oven (GINKYA IM 3500 
series), ambient temperature and humidity. Drug content of all the formulations was determined after 15 day, 
30 day and 60 day. In vitro release study of a selected formulation was also carried out after storage for 1 
month
22
  The release data obtained for pure drug, marketed preparation and formulations F1, F2, F3 and F4 are 
showed in Fig. 2 It shows plots of cumulative percent drug released as a function of time for pure drug and 
for different formulations of 5 – fluorouracil loaded microspheres. When compared with pure drug and 
.  
 
RESULTS AND DISCUSSION 
Different magnifications were used while taking these photomicrographs. Average particle size of magnetic 
microspheres of 5 - fluorouracil was found to be 3.27 + 0.0766, 5.39 + 0.1932, 7.61 + 0.846, 12 + 0.1066 µ 
for F1 to F4 respectively. Particles of formulations F1, F3 and F4 were found to be smooth, oval and discrete 
whereas particles of formulation  F2  were slightly rough surfaced but discrete.  Scanning electron 
photomicrographs of formulations F2 is shown in Fig. 1. 
Drug entrapment efficiency was calculated from the drug content. The mean practical yield for all the 
formulations was more. A positive correlation between solid content and percentage yield was observed. This 
may be explained by the fact that through a constant amount of material is always lost in processing, this loss 
is proportionately less significant when the solid content is more (e.g. if the loss in processing is 15 mg then 
it is significant for a 100 mg sample, but much less significant for 500 mg sample). It was observed that 
entrapment efficiency was increased with increase in concentration of polymer added in formulations. The 
maximum drug content was found in F2 i.e. 89.59 % and minimum drug content was found in F1. The 
percentage drug loading and drug entrapment efficiency of all the formulations were given in the Table1. 
Pure 5 – fluorouracil, marketed preparation and all the four formulations of 5 - fluorouracil loaded 
microspheres were subjected to in vitro release studies. These studies were carried out in PBS pH 7.4. The 
cumulative percent drug release of pure drug and marketed preparation was found to be 91.3 % and 85.58 % 
respectively at 3 hr. Cumulative percent drug release after 12 hr was 86.41 %, 92.84 %, 79.88 % and 82.38 % 
for F1, F2, F3 and F4 respectively by UV spectroscopy.  Mudgal S et al / IJRAP 2010, 1 (1) 160-168 
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marketed formulation, the release of 5-fluorouracil loaded microspheres was prolonged over a period of 12 hr 
or more. The in-vitro release of all the four batches of microspheres showed an interesting bi-phasic release 
with an initial burst effect. In the first 30 mins, drug release was 18.4 %, 20 %, 14.4 % and 16.4 % for F1, F2, 
F3 and F4 respectively. This was followed by a steady drug release pattern, which approximated zero order 
release. The mechanism for the burst release can be attributed to the drug loaded on the microspheres or 
imperfect entrapment of drug. It was observed that the drug release from the formulations decreased with 
increase in the amount of polymer added in each formulation. 
Formulation F2 with highest drug content was selected for in-vivo drug targeting studies. The comparison 
between the amount of drug targeted from microspheres and free drug in various organs is presented in Fig. 
3. The average targeting efficiency of drug loaded microspheres was found to be 26.16 % of the injected dose 
in liver, 11.40 % in lungs, and 15.08 % in spleen, whereas the concentration of pure drug was 15.52 % in 
liver, 9.0 % in lungs, and 9.50 % in spleen. These results reveal that the drug loaded microspheres showed 
preferential drug targeting to liver followed by spleen and lungs. It was also revealed that as compared to 
pure drug, higher concentration of drug was targeted to the organs after administering the dose in form of 
microspheres. Higher drug targeting in liver and spleen as compared to lungs may be attributed to high 
macrophages load in these organs and large size of liver as compared to spleen and lungs. Accumulation of 
drug in lungs could be also due to physical entrapment of the microspheres.  
Stability studies of the prepared microspheres were carried out, by storing all the formulations F1 to 
F4 at 4ºC in refrigerator, ambient temperature and humidity and 30ºC ± 2ºC / 65 % RH ± 5 % RH in 
humidity control oven for 60 day. Two parameters namely residual percent drug content and in vitro release 
studies were carried out. The results of drug content after 15 day, 30 day and 60 day are shown in Table no.2. 
These studies reveal that there is a reduction in drug content after storage for 60 days at 4ºC, ambient 
temperature and humidity and 30ºC  ±  2ºC / 65 % RH ± 5 % RH. It was also revealed that out of the four 
formulated batches, the one stored at 4º showed maximum residual drug followed by that stored at ambient 
temperature and humidity and 30º C  ±   2ºC / 65 % RH ± 5 % RH. In vitro release studies, which were 
carried out after storing a selected formulation F2 at 4º, ambient temperature and humidity and 30ºC  ±  2ºC / 
65 % RH ± 5 % RH for 60 day. In vitro release studies reveal that the formulation stored at 4º showed 86.15 
% release, the one which stored at ambient temperature and humidity showed 85.13 % and formulation 
stored at 30ºC ±  2ºC / 65 % RH ± 5 % RH showed 83.93 % release after 12 hr. On comparing this data with 
the previous release data of F2, it was observed that there was maximum drug content and closest in vitro 
release. Thus, it can be concluded that 4°C  is the most suitable temperature for storage 5-FU loaded 
microspheres. 
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Table No.1- Percentage Practical Yield and Drug Entrapment Efficiency 
 
Formulations  Practical yield (%)  Drug entrapment efficiency (%) 
F1  79.4   ± 0.221  63.2 ± 0.168 
F2  89.59 ± 0.223  68.9 ± 0.214 
F3  88.33 ± 0.268  79.4 ± 0.257 
F4  83.76 ± 0.321  78.8 ± 0.355 
Each value represents mean ±SD for (n=3) 
 
Table No. 2 - Stability studies for percent drug content 
(After storage at 4ºC, ambient temperature and humidity and at 30ºC / 65 % RH) 
 
Formulations 
Percent drug content at 
 4º C 
Percent drug content at 
ambient temperature and 
humidity 
Percent drug content at 
30º C / 65% RH 
After 15 
days 
After 
30 days 
After 
60 
days 
After 
15 
days 
After 
30 
days 
After 
60 
days 
After 
15 
days 
After 
30 
days 
After 
60 
days 
F1 
39.74 
± 
0.322 
39.62 
± 
0.300 
38.88 
± 
0.315 
39.36 
± 
0.325 
39.10 
± 
0.291 
38.54 
± 
0.285 
39.30 
± 
0.301 
38.95 
± 
0.299 
38.30 
± 
0.283 
F2 
46.64 
± 
0.385 
46.38 
± 
0.389 
45.64 
± 
0.379 
46.29 
± 
0.380 
45.89 
± 
0.382 
45.12 
± 
0.370 
46.25 
± 
0.387 
45.76 
± 
0.368 
44.62 
± 
0.360 
F3 
53.02 
± 
0.522 
52.88 
± 
0.495 
52.26 
± 
0.530 
52.96 
± 
0.520 
52.32 
± 
0.548 
51.96 
± 
0.498 
52.88 
± 
0.495 
52.15 
± 
0.501 
51.58 
± 
0.488 
F4 
65.18 
± 
0.551 
56.04 
± 
0.549 
55.38 
± 
0.541 
56.14 
± 
0.545 
55.94 
± 
0.540 
54.78 
± 
0.499 
56.08 
± 
0.501 
55.70 
± 
0.544 
54.42 
± 
0.498 
Each value represents mean ±SD for (n=3) 
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Fig 1. Scanning electron photomicrographs of formulations F2 
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Fig 2. In vitro release profile for different formulations of 5-fluorouracil from microspheres. 
Pure drug (--), Marketed preparation (-■-), Formulation F1 (-▲-),  
Formulation F2 (--), Formulation F3 (--), Formulation F4 (-*-) 
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Fig 3. In vivo profile of formulation F2 in various organs. 
Comparison of   % drug content and free drug in various organs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source of support: Nil, Conflict of interest: None Declared 
 